• Home
• Collaborations
• SR One

SR One

Applying insight. Creating value
SR One is GlaxoSmithKline's independent corporate healthcare venture capital fund. We invest globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that will have a dramatic benefit to patients.

We have a team of investment professionals, located in the US and Europe. As a Team, our experience spans basic science, industry and the market.

We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Our current portfolio includes approximately 25 private and public companies and since our founding in 1985, we have invested over $560MM in the biotech space.

Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.

Visit the SR One website to find out more.